Search Results
Your search for early matches 10493 pages
Showing 3851 - 3900PORTEC-3: Effect of Molecular Classification of Endometrial Cancer on Outcomes With Adjuvant Therapy
In a study reported in the Journal of Clinical Oncology, Alicia Léon-Castillo, MD, of Leiden University Medical Center, the Netherlands, and colleagues identified outcomes associated with molecular subgroups of patients with high-risk endometrial cancer enrolled in the PORTEC-3 trial of adjuvant...
Expert Point of View: Kathleen N. Moore, MD
Kathleen N. Moore, MD, Associate Professor of Gynecologic Oncology and Director of the Oklahoma TSET Phase I Clinical Trials Program, Stephenson Cancer Center, Oklahoma City, underscored the importance of studying patients with stable disease and less robust partial response, not just those with...
SGO 2020: Updated Analysis of VELIA Trial Shows Antitumor Activity in Ovarian Cancer, but Is It Enough?
An updated analysis of the phase III VELIA/GOG-3005 trial, presented during the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer Webinar Series,1 suggested synergy between the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib and platinum chemotherapy in the...
Expert Point of View: Thomas J. Herzog, MD
Thomas J. Herzog, MD, Deputy Director, University of Cincinnati Cancer Center, who presented a distillation of the PRIMA trial data along with updated results of the phase III PAOLA-1 trial of olaparib plus bevacizumab maintenance, called the data “practice-changing.” “We’ve suspected for a while...
SGO 2020: Updated Data From PRIMA Trial: Niraparib as First-Line Maintenance Therapy for Advanced Ovarian Cancer
Making sense of maintenance therapy in advanced ovarian cancer has been a tall order since the publication of impressive data for not one but three poly (ADP-ribose) polymerase (PARP) inhibitors at the European Society for Medical Oncology (ESMO) 2019 Congress.1 The picture became a little clearer...
Clinical Perspective on PAOLA-1: Maintenance Therapy for Advanced Ovarian Cancer
Based on multiple phase III prospective trials, there is evidence that both poly (ADP-ribose) polymerase (PARP) inhibitors and antiangiogenic therapies such as bevacizumab provide benefit when utilized in a maintenance strategy in the first-line treatment of advanced epithelial ovarian cancer (GOG...
Does Binimetinib Improve Progression-Free Survival in Recurrent or Persistent Low-Grade Serous Ovarian Carcinomas?
As reported in the Journal of Clinical Oncology by Bradley J. Monk, MD, and colleagues, the phase III MEK Inhibitor in Low-Grade Serous Ovarian Cancer (MILO)/ARRAY-162-311/ENGOT-ov11 trial showed that the MEK1/2 inhibitor binimetinib did not improve progression-free survival vs physician’s choice...
Risk‐Reducing Early Salpingectomy and Delayed Oophorectomy Among Premenopausal Women
A study published by Gaba et al in BJOG: An International Journal of Obstetrics and Gynaecology has found that risk‐reducing early salpingectomy and delayed oophorectomy is highly acceptable among premenopausal women at increased risk for developing ovarian cancer—particularly among patients...
FDA Approves Oral Azacitidine as Maintenance Therapy for Adults With AML in First Remission
On September 1, the U.S. Food and Drug Administration (FDA) approved oral azacitidine (Onureg; also known as CC-486) for the continued treatment of adult patients with acute myeloid leukemia (AML) who achieved first complete remission or complete remission with incomplete blood count recovery...
Changes in Reoperation Rates After Publication of SSO/ASTRO Guideline on Margins for Breast-Conserving Surgery
In a meta-analysis reported in JAMA Surgery, Marinovich et al found that reoperation rates after breast-conserving surgery in women with breast cancer declined after the publication of the Society of Surgical Oncology/American Society for Radiation Oncology (SSO/ASTRO) Consensus Guideline on...
Is It Time to Add Checkpoint Inhibitors to the Treatment of Locally Advanced Lung Cancer?
After more than 20 years of failed strategies to improve survival rates for locally advanced lung cancers, checkpoint inhibitors have revolutionized therapy, but prognoses still lag behind other tumor types. During the ASCO20 Virtual Education Program, Mark G. Kris, MD, FASCO, a thoracic medical...
Are Patients With Hematologic Cancers More Vulnerable to the Effects of COVID-19?
A new study from the UK Coronavirus Cancer Monitoring Project (UKCCMP) has found that, compared with patients who have other malignancies, patients with blood cancers are more vulnerable to the effects of COVID-19 infection. These results were published by Lee et al in The Lancet Oncology. As...
Metastatic Prostate Cancer: Sorting Through the Treatment Maze
The message still needs to get out that metastatic castration-sensitive prostate cancer should be treated with both androgen-deprivation therapy (ADT) and either docetaxel or an androgen receptor pathway inhibitor. In spite of “overwhelming” support for ADT plus abiraterone/prednisone,...
Acupuncture vs Sham Procedure and Usual Care for Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy is a debilitating and enduring adverse effect of many antineoplastic agents, which negatively impacts the quality of life of patients with cancer and survivors. Current pharmacotherapy has limited efficacy and causes undesirable effects. In this...
Austrian Study of SARS-CoV-2 Testing in Patients With Cancer Treated at a Tertiary Care Hospital During the COVID-19 Pandemic
In an Austrian study reported in the Journal of Clinical Oncology, Berghoff et al found that 0.4% of consecutive patients with cancer treated at Medical University of Vienna tested positive for SARS-CoV-2 between March 21 and May 4, 2020, after implementation of institutional and governmental...
Breast Cancer Survival Is Significantly Decreased Among Premenopausal Women Previously Treated With Radiation for Childhood or AYA Cancer
Although radiotherapy is integral to the multidisciplinary therapy used in the treatment of common childhood and adolescent and young adult (AYA) cancers, including Hodgkin lymphomas, sarcomas, and breast cancer, the treatment is a strong risk factor for a secondary breast malignancy, especially...
Developing Policies to Address Patient Racial Bias and Race-Based Provider Requests
Public momentum for efforts to address structural and systemic racism has led many health-care institutions to consider how they can work to bring about positive change. In this column, drawing on important recent work by Kimani Paul-Emile, JD, PhD, Professor of Law at Fordham University School of ...
From Behind the Iron Curtain to a Career in Gynecologic Cancer Research for Daniela Matei, MD
Daniela Matei, MD, Diana, Princess of Wales Professor of Cancer Research at Northwestern Feinberg School of Medicine, Chicago, grew up Sibiu, a picturesque Romanian city situated at the foothills of the Cindrel Mountains in historic Transylvania. “Both of my parents were physicians, and some of my ...
Transoral Robotic Surgery May Improve Outcomes in Early-Stage Oropharyngeal Cancer
Robotic surgery for patients with early-stage oropharyngeal squamous cell cancer may be associated with improved health outcomes, including better long-term survival, according to a study published by Nguyen et al in JAMA Oncology. Transoral robotic surgery is a minimally invasive procedure in...
Sanjiv Sam Gambhir, MD, PhD, Pioneer in Molecular Imaging, Dies at 57
Sanjiv Sam Gambhir, MD, PhD, Professor and Chair of Radiology at the Stanford School of Medicine and an internationally recognized pioneer in molecular imaging, died on July 18, 2020, of cancer. He was 57. The Virginia and D.K. Ludwig Professor of Cancer Research, Dr. Gambhir dedicated his career...
Anticipate Difficulties by Patients in Adhering to Tamoxifen Therapy
Patients prescribed tamoxifen may not report when they interrupt or discontinue therapy, according to the results of a study published in the Journal of Clinical Oncology.1 Using blood draws to determine serum levels of tamoxifen among 1,177 premenopausal women with invasive breast cancer, the...
One in Six Premenopausal Women With Invasive Breast Cancer Is Nonadherent to Tamoxifen Therapy
Measuring serum levels of tamoxifen among premenopausal women being treated for invasive breast cancer identified a “worryingly high proportion of patients, one in six, who were nonadherent to therapy at only 1 year after treatment prescription,” researchers reported in the Journal of Clinical...
Tumeur Fibro-Plastique
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Anesthesia Era 1845–1875 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...
Dana-Farber Launches New Center for Prevention and Treatment of BRCA-Related Cancers
Of the tens of thousands of genes in cellular DNA, one group of genes is tasked with ensuring that every cell reproduces itself exactly when it divides to make new cells. Perhaps the best known of these genes are the BRCA genes, which if inherited with a significant alteration, confer a markedly...
After Immigrating From India, Neha Vapiwala, MD, FACR, Followed Her Dream of a Career in Medicine
Neha Vapiwala, MD, FACR, Professor and Vice Chair of Education in the Department of Radiation Oncology and newly appointed Dean of Admissions at the Perelman School of Medicine at the University of Pennsylvania (UPenn), Philadelphia, was born in India to parents who aspired to emigrate to the...
Ashwagandha
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Gary Deng, MD, PhD, and Jyothirmai Gubili, MS, present updated information on ...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Cambodia
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Cambodia. The aim of this special feature is to highlight the global cancer burden for various countries of the...
Penn Medicine Receives $4.9 Million Grant to Improve Uptake of Cancer Care Best Practices
Although extensive research has suggested ways to ensure that patients receive evidence-based cancer care, putting these solutions into widespread practice can be a complex, challenging, and inefficient process. Now, a new grant awarded to the Perelman School of Medicine at the University of...
Managing Cancer in Older Adults During the COVID-19 Pandemic
The COVID-19 pandemic is an additional competing risk to factor in when making decisions about anticancer treatment for older adults. It poses a potential barrier to equal and evidence-based management of cancer in this group of patients. Implementing geriatric assessments in routine clinical...
Association of Community Cancer Centers Announces 2020 Innovator Award Recipients
The Association of Community Cancer Centers (ACCC) announced the winning programs for its 10th annual ACCC Innovator Awards, highlighting the year’s leading-edge strategies to challenges faced by oncology programs and practices across the country. The eight ACCC Innovator Award winners feature...
David A. Karnofsky’s Early Contributions to Cancer Research Helped Establish Oncology as a Medical Discipline
For nearly 30 years, from the time he was a young resident at the Collis P. Huntington Memorial Hospital for Cancer Research of Harvard University, until his death from lung cancer on August 31, 1969, David A. Karnofsky, MD, dedicated himself to the pursuit of scientific excellence and the...
How to Treat Patients With Multiple Myeloma Cost-Effectively Without Compromising Outcome
The dramatic advances in the diagnosis and treatment of multiple myeloma over the past 20 years have resulted in significant improvements in overall survival, with 5-year relative survival rates now around 50% and more than 60% for patients younger than age 70.1 The proteasome inhibitors...
How the First International Summit on Interventional Pharmacoeconomics Is Sparking Discussion on Reducing Cancer Costs
Three years ago, former Chief Executive Officer of ASCO, Allen S. Lichter, MD, Laurence H. Baker, DO, Professor in the Departments of Internal Medicine and Pharmacology at the University of Michigan Medical School in Ann Arbor; Leonard Saltz, MD, a gastrointestinal oncologist at Memorial Sloan...
Into the Ring With Tap Cancer Out
Brazilian jiu-jitsu (BJJ) athletes use combat techniques designed to dominate one’s opponent with control and force. The goal: make your opponent be the first to tap out. In 2010, BJJ practitioner Jon Thomas was surprised to discover there was no philanthropic presence within his sport. That’s when ...
BRCA Study: Clinic Is Saving Men’s Lives in Israel
Uriya, age 49, visits Israel’s Rabin Medical Center for a cancer screening. On the surface, he shows no signs of disease. However, results from a study by David Margel, MD, PhD, revealed Uriya is living with prostate cancer at an early yet curable stage. Uriya carries the BRCA gene. Rabin Medical...
For Your Patients: An Expert Q&A on Cancer Disparities and Health Equity
Cancer does not affect all people equally. The phrase “cancer disparities” refers to the differences in the number of new cancer cases as well as differences in cancer outcomes that exist among different populations. Disparities more often negatively affect racial and ethnic minorities, poor...
Final ASCEND Results Confirm Acalabrutinib as a Standard for Relapsed CLL
The Bruton’s tyrosine kinase (BTK) inhibitors have been one of the most exciting advances in the tre atment of chronic lymphocytic leukemia (CLL) and have led to the development of chemotherapy-free treatments for both treatment-naive as well as relapsed or refractory CLL based on studies where...
Acalabrutinib Improves Progression-Free Survival vs Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory CLL
As reported in the Journal of Clinical Oncology by Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele, Milan, Italy, and colleagues, the phase III ASCEND trial showed significantly prolonged progression-free survival with acalabrutinib monotherapy vs the investigator’s choice of...
Researchers Outline Need for Evaluation of Gene-Expression Profiling in Melanoma
A consensus statement published in JAMA Dermatology by an international group of melanoma researchers evaluated the use of prognostic gene-expression profile testing to guide clinical management of melanoma.1 The group cautioned against the routine use of currently available gene-expression...
Bert W. O’Malley, Jr, MD, Named President and Chief Executive Officer of the University of Maryland Medical Center
Following an extensive national search, Bert W. O’Malley, Jr, MD, has been appointed as the new President and Chief Executive Officer of the University of Maryland Medical Center (UMMC), the flagship academic hospital for the University of Maryland Medical System and an anchor institution in...
Repurposing Drugs for the Treatment of COVID-19
A vaccine for COVID-19 is currently the Holy Grail, but even if an effective vaccine were developed on a fast-track timetable, it may be effective in only a percentage of people, judging by existing flu vaccines, which show efficacy rates of approximately 45% and vary year by year. Until we have a...
Ripretinib Improves Progression-Free Survival vs Placebo in Previously Treated Advanced GIST
As reported inThe Lancet Oncology by Jean-Yves Blay, MD, of Centre Léon Bérard, Lyon, France, and colleagues, the phase III INVICTUS trial has shown that the oral KIT and PDGFRα tyrosine kinase inhibitor ripretinib significantly prolonged progression-free survival vs placebo in patients with...
ASCO Provisional Clinical Update Offers New Recommendations for HBV Management in Patients With Cancer
Oncologists should consider screening all patients with cancer for the hepatitis B virus (HBV) prior to starting systemic anticancer therapy, with a focus on tests that use the hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), total Ig or IgG, and antihepatitis B surface...
Reevaluating the Delivery of Palliative Care in the Era of COVID-19
Palliative care services are so crucial to the well-being of patients with cancer that, in 2017, ASCO updated its clinical practice guideline on the integration of palliative care into standard oncology care.1 The updated guideline recommends that all patients with advanced cancer receive dedicated ...
Past CMS and FDA Head Discusses Challenges in U.S. Health-Care Policy and Possible Solutions
As evidenced at this year’s ASCO20 Virtual Scientific Program, oncology science, technology, and clinical practice are evolving at a rapid pace, bringing new challenges to the efficient and ethical practice of cancer care at all levels. To shed light on some of the large-scale public health and...
ASCO Updates Metastatic Pancreatic Cancer Guideline
ASCO has released an update to its Metastatic Pancreatic Cancer Guideline that includes recommendations for second-line treatment, including early biomarker testing for actionable genomic alterations.1 Last updated in 2018, this new version was triggered by novel evidence related to targeted...
Study Finds Treatment Delays for Patients With Breast Cancer Early in the COVID-19 Pandemic
The results of an online questionnaire of 609 breast cancer survivors in the United States suggest that nearly half of patients experienced delays in care during the early weeks of the COVID-19 pandemic. The study was published by Papautsky et al in the journal Breast Cancer Research and ...
Tumor Mutational Burden and the Future of Complex Biomarkers
The development of complex biomarkers such as tumor mutational burden (TMB) has enabled clinicians to identify patients more likely to respond to treatment of a variety of cancers, leading to more accurate diagnoses and improved outcomes. Differences in testing assays, however, have produced...
Molecular Testing in Metastatic Colorectal Cancer: Understanding How, When, and What to Profile
“In line with the emergence of targeted therapies, molecular biomarker testing in metastatic colorectal cancer has evolved over the past decade,” noted Jeanne Tie, MD, MBChB, FRACP, who acknowledged there is confusion about the best ways to use molecular testing in the clinic. Dr. Tie, who is...
Genomic Analysis of Cervical Cancer in Ugandan Patients
Nineteen of the 20 nations with the highest cervical cancer death rates are in sub-Saharan Africa. Now an international team has published the first comprehensive genomic study of cervical cancers in sub-Saharan Africa, with a focus on tumors from 212 Ugandan patients with cervical cancer. Their...
